Encefalitis por anticuerpos antirreceptor N-metil-D-aspartato
DOI:
https://doi.org/10.51481/amc.v58i3.929Palabras clave:
autoimmune encephalitis, anti NMDA-receptor encephalitis, paraneoplastic encephalitis, neuropsychiatric disordersResumen
La encefalitis por anticuerpos antirreceptor N-metil-D-Aspartato pertenece a un grupo de enfermedades que inicialmente se llamaban encefalitis límbicas, hoy conocidas como encefalitis autoinmunes. Se caracterizan por estar frecuentemente asociadas a algún tumor, responder a la inmunoterapia y provocar daños cerebrales variables que se manifiestan como cuadros clínicos polimorfos (desde la disfunción límbica hasta una encefalopatía multifocal o difusa). Algunos pacientes con condiciones psiquiátricas agudas podrían tener en realidad una encefalitis autoinmune, sin embargo, no es tan fácil sospecharlo con las manifestaciones iniciales. Su incidencia exacta no se conoce, pero cada vez hay más reportes de casos. Sus características clínicas están bien descritas y evolucionan en cinco fases. El diagnóstico definitivo se hace al obtener la confirmación serológica de los anticuerpos, pero hay algunas pruebas que pueden orientar la sospecha diagnóstica. El tratamiento se basa en esteroides y otros inmunosupresores.
Descargas
Citas
Diamond B, Honig G, Mader S, Brimberg L, Volpe B. Brain-Reactive Antibodies and Disease. Annu Rev Immunol. 2013;31:345–85.
Gutiérrez A, Barboza M. Encefalitis por anticuerpos contra el receptor N– metil–D–aspartato: presentación de un caso. Rev Cubana Neurol Neurocir. 2013; 3:83-87.
Benarroch E. NMDA receptors: Recent insights and clinical correlations. Neurology. 2011; 76:1750-1757.
Brierley J, Corsellis J, Hierons R, Nevin S. Subacute encephalitis of later adult life. Mainly affecting the limbic areas. Brain. 1960; 83: 357-368.
Corsellis J, Goldberg G., Norton A. Limbic encephalitis and its association with carcinoma. Brain. 1968; 91:481-496.
Wandinger K, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol. 2011; 231:86-91.
Vincent A, Buckley C, Schott J, Baker I, Dewar B, Detert N, Palace J. Potassium channel antibody-associated encephalopathy: a potentially immunotherapyresponsive form of limbic encephalitis. Brain. 2004; 127: 701-712.
Malter M, Helmstaedter C, Urbach H, Vincent A, Bien C. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010; 67:470–478.
Santiesteban N, Merayo R. Encefalitis sinápticas autoinmunes. Rev Mex Neuroci. 2011; 12:204-209.
Lancaster E, Dalmau J. Neuronal autoantigens—pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012; 8:380-390.
Peery H, Day G, Prüss H, De Souza C, Foster L. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmu Rev. 2012; 11:863–872.
Ramanathan S, Mohammada S, Brilot F, Dale R. Autoimmune encephalitis: Recent updates and emerging challenges. J Clin Neurosc. 2014; 21:722-730.
Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005; 58:594-604.
Dalmau J. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61:25-36.
Dalmau J, Gleichman A, Hughes E, Ross J, Peng X, Lai M, Lynch D. AntiNMDA-receptor encephalitis: case series and analysis of the eff ects of antibodies. Lancet Neurol. 2008; 7:1091-1098.
Marques I, Teotónio R, Cunha C, Bento C, Sales F. Anti-NMDA receptor encephalitis presenting with total insomnia – A case report. J Neurol Sci. 2014; 336, 276–280.
Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein H, Vielhaber S, et al. Increased Prevalence of Diverse N-Methyl-D-Aspartate Glutamate Receptor Antibodies in Patients With an Initial Diagnosis of Schizophrenia. JAMA Psichiatry. 2013; 70:271-278.
Choe C, Karamatskos E, Schattling B, Leypoldt F. A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder. Psychiatry Res. 2013; 208:194–196.
Kuo Y, Tsai H, Lai M, Lin C, Yang K. Anti-NMDA receptor encephalitis with the initial presentation of psychotic mania. J Clin Neurosci. 2012; 19;896–898.
Iizuka T, Sakai F, Monzen T, Yoshii S, Iigaya M, Dalmau J. Anti-NMDA receptor encephalitis in Japan: Long-term outcome without tumor removal. Neurology. 2008; 70:504–511.
Dalmau J, Lancaster E, Martinez E, Rosenfeld M, Balice R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011; 10:63-74.
Levite, M. Glutamate receptor antibodies in neurological diseases: antiAMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, en. J Neural Transm. 2014; 121:1029-75.
Miya K, Takahashi Y, Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev. 2014; 36:645–652.
Gleichman A, Spruce L, Dalmau J, Seeholzer S, Lynch D. Anti-NMDA Receptor
Encephalitis Antibody Binding Is Dependent on Amino Acid Identity of a Small Region within the GluN1 Amino Terminal Domain. J Neurosci. 2012; 32:11082–11094.
Hughes E, Peng E, Gleichman A, Lai M, Zhou L, Tsou R, et al. Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis. J Neurosci. 2010; 30:5866 –5875.
Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis, Further evidence of synaptic glutamatergic dysfunction. Orphanet J of Rare Dis. 2010; 5:1-12.
Maneta E, Garcia G. Psychiatric Manifestations of Anti-NMDA Receptor Encephalitis. Neurobiological Underpinnings and Differential Diagnostic Implications. Psychosomatics. 2014; 55:37-44.
Schmitt S, Pargeon K, Frechette E, Hirsch L, Dalmau J, Friedman D. Extreme delta brush. A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012; 79:1094–1100.
González J, Rosenfeld M, Dalmau J. Diagnóstico diferencial en la encefalitis por anticuerpos contra el receptor NMDA. Neurología. 2010; 25:409-413.
Day G, High S, Cot B, Tang D. Anti-NMDA-Receptor Encephalitis: Case Report and Literature Review of an Under-Recognized Condition. J Gen Intern Med. 2011; 26:811–6.
Granerod J, Ambrose H, Davies N, Clewley J, Walsh A, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England. A multicentre, population-based prospective study. Lancet Infect Dis. 2010; 10: 835–44.
Ingram G, Robertson N. Antibody mediated encephalitis. J Neurol. 2013; 260:1187–1190.
Titulaer M, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al.
Treatment and prognostic factors for long-term outcome in patients with antiNMDA receptor encephalitis: An observational cohort study. Lancet Neurol. 2013; 12: 157–65.
Chapman M, Vause H. Anti-NMDA Receptor Encephalitis, Diagnosis, Psychiatric Presentation, and Treatment. American Journal of Psychiatry. 2011; 168: 245-251.
Breese E, Dalmau J, Lennon V, Apiwattanakul M, Sokol D. Anti-N-Methyl-dAspartate Receptor Encephalitis: Early Treatment is Beneficial. Pediatr Neurol. 2009; 42: 213-214.
Braakman H, Moers V, Arts B, Hupperts R, Nicolai J. Pearls & Oy-sters: Electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurology. 2010; 75:e44-e46.
Gabilondo I, Saiz A, Galán L, González V, Jadraque R, Sabater V, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011; 77:996–999.
Publicado
Versiones
- 2016-07-01 (2)
- 2016-11-10 (1)
Cómo citar
Número
Sección
Licencia
Derechos de autor 2016 Acta Médica Costarricense
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
